WuXi XDC Secures GMP Release for Singapore Facility

WuXi XDC Cayman Inc. has officially celebrated the GMP release of its new manufacturing facility in Singapore. This milestone signifies the company's continued global expansion and its commitment to meeting the growing demand for bioconjugate drug development and manufacturing.

The Singapore facility is designed to handle the production of complex bioconjugates, including antibody-drug conjugates (ADCs), adhering to stringent Good Manufacturing Practice (GMP) standards. This expansion is expected to enhance WuXi XDC's service offerings and strengthen its supply chain capabilities for its international client base.

The successful commissioning of the site follows significant investment and development, reinforcing WuXi XDC's role as a contract research, development, and manufacturing organization (CRDMO) in the specialized bioconjugate sector. The company aims to accelerate the delivery of novel therapeutics to patients worldwide.

This strategic addition to WuXi XDC's operational network aims to improve its capacity and efficiency in serving a global clientele. The company operates multiple facilities to support the biopharmaceutical industry's needs for advanced drug substance and drug product manufacturing.